Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorDenver Health and Hospital Authority

About this trial

To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients diagnosed with an eating disorder diagnosis that includes purging history

Ages 18-65

Purging history =>5 years

Purging or rumination at a minimum of once daily upon admission.

Disqualifiers

Any eating disorder diagnosis that does not include purging behaviors

Ages under 18 and over 65

Patients who otherwise meet the current ACG screening guidelines (chronic GERD and 3 or more risk factors for Barrett's mentioned in the Background)

Received mandated care at time of enrollment

Trial population

ACUTE patients with a confirmed dx of AN-BP, with a purging history of \>5 year, with a frequency of purging of at least once a day.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • EsoGuard

    Device

    device used to collect esophageal cell samples to test for the presence of abnormal cells which may indicate a dx of Barrett's esophagitis.

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: AN-BP1 intervention

Trial outcomes

Primary outcomes

1

Number of patients positive for BE

Individuals with severe forms of eating disorders with purging and ruminating behaviors not meeting a current screening guidelines for BE will test positive for BE

Time frame
12 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Denver Health and Hospital Authority

Lead sponsor

Lucid Diagnostics, Inc.

Collaborator